Sec. 3. (a) As used in this chapter, "biomarker" means a characteristic that is objectively measured and evaluated as an indicator of:
(1) normal biological processes; (2) pathogenic processes; or (3) pharmacologic responses to a specific therapeutic intervention, including known gene-drug interactions for medications being considered for use or already being administered. (b) The term includes gene mutations, characteristics of genes, and protein expression. As added by P.L.37-2024, SEC.2.